<area date-time="f23s7h"></area> Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2009 Jan 8;113(2):273-8.
doi: 10.1182/blood-2008-07-167098. Epub 2008 Oct 2.

A biomarker panel for acute graft-versus-host disease

Sophie Paczesny  1 , Oleg I Krijanovski, Thomas M Braun, Sung W Choi, Shawn G Clouthier, Rork Kuick, David E Misek, Kenneth R Cooke, Carrie L Kitko, Angela Weyand, Daniel Bickley, Dawn Jones, Joel Whitfield, Pavan Reddy, John E Levine, Samir M Hanash, James L M Ferrara
Affiliations

A biomarker panel for acute graft-versus-host disease (V体育2025版)

Sophie Paczesny et al. Blood. .

V体育ios版 - Abstract

No validated biomarkers exist for acute graft-versus-host disease (GVHD). We screened plasma with antibody microarrays for 120 proteins in a discovery set of 42 patients who underwent transplantation that revealed 8 potential biomarkers for diagnostic of GVHD. We then measured by enzyme-linked immunosorbent assay (ELISA) the levels of these biomarkers in samples from 424 patients who underwent transplantation randomly divided into training (n = 282) and validation (n = 142) sets. Logistic regression analysis of these 8 proteins determined a composite biomarker panel of 4 proteins (interleukin-2-receptor-alpha, tumor-necrosis-factor-receptor-1, interleukin-8, and hepatocyte growth factor) that optimally discriminated patients with and without GVHD. The area under the receiver operating characteristic curve distinguishing these 2 groups in the training set was 0. 91 (95% confidence interval, 0. 87-0. 94) and 0 VSports手机版. 86 (95% confidence interval, 0. 79-0. 92) in the validation set. In patients with GVHD, Cox regression analysis revealed that the biomarker panel predicted survival independently of GVHD severity. A panel of 4 biomarkers can confirm the diagnosis of GVHD in patients at onset of clinical symptoms of GVHD and provide prognostic information independent of GVHD severity. .

PubMed Disclaimer

Figures (VSports)

Figure 1
Figure 1
ELISA heat map of discovery set samples. We performed sequential ELISA as described in “Antibody array methods” on samples from 21 GVHD− patients (left panel) and 21 GVHD+ patients (right panel) of the discovery set that were analyzed by microarray in Figure S1. Gray indicates that the sample was not assayed for that protein. Levels of PSA-ACT, IL-17, and IL-1β were not detectable and therefore do not appear in the figure. We measured tumor-necrosis-factor-receptor-1 (TNFR1) rather than TNF-α because of its close correlation to TNF-α and documented reproducibility of measurement in previously frozen samples. P values compare GVHD+ and GVHD− samples.
Figure 2
Figure 2
Concentrations of 4 individual discriminator proteins, their receiver operating characteristic (ROC) curves, and the composite panel ROC curves. (A) Absolute values on a logarithmic scale of soluble IL-2Rα, TNFR1, HGF, and IL-8 in samples from the training with their medians and ranges. Patients without GVHD (−) versus with GVHD (+): P < .001. (B) Individual ROC curves for IL-2Rα (----), TNFR1 (—), HGF (.-.-.), and IL-8 (.....) and the composite panel (—). (C) ROC curves of the composite panel for the training set (—) and the validation set (- - - -). The cross separates patients into 2 groups based on their predicted probability of GVHD (high and low) with a specificity of 95% in the training set and 94% in the validation set.
Figure 3
Figure 3
Nonrelapse mortality and overall survival stratified by the biomarker panel. (A) The cumulative incidence of nonrelapse mortality (NRM) and overall survival (OS), determined by Kaplan-Meier curve, is plotted according to the predicted probability of acute GVHD: low (—, n = 193) and high (----, n = 89). P = .001 and P = .006 (adjusted for age, donor type, HLA match, and intensity of conditioning) for differences in NRM and OS, respectively. The NRM at 3.5 years is 15% (95% CI, 9%-21%) for the low-risk group and 36% (95% CI, 24%-48%) for the high-risk group. OS at 3.5 years is 53% (95% CI, 45%-63%) for the low-risk group and 33% (95% CI, 22%-48%) in the high-risk group. (B) The cumulative incidence of NRM and OS of the 2 groups is plotted for the validation set: low (—, n = 93) and high (----, n = 49). P values less than .001 and .02 (adjusted as before) for differences in NRM and OS, respectively. The NRM at 3.5 years is 11% (95% CI, 4%-19%) for the low-risk group and 38% (95% CI, 23%-53%) for the high-risk group. OS at 3.5 years is 59% (95% CI, 49%-72%) for the low-risk group and 44% (95% CI, 31%-63%) for the high-risk group.
See this image and copyright information in PMC

"V体育ios版" Comment in

"VSports" References

    1. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828. - PubMed
    1. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821–1828. - PubMed
    1. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17:185–190. - PubMed
    1. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant. 1998;21:29–32. - "VSports app下载" PubMed
    1. Foley R, Couban S, Walker I, et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant. 1998;21:769–773. - "V体育2025版" PubMed

VSports注册入口 - Publication types

MeSH terms